FDA extends regulatory review period for IDegLira by three months

**Bagsværd, Denmark, 2 September 2016** – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with type 2 diabetes.

The FDA informed Novo Nordisk that a three-month extension was required in order to complete its review of the new drug application (NDA) for IDegLira.

Novo Nordisk submitted the NDA to the FDA in September 2015, and with the extension of the review the action date is now expected in December 2016.

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.*

**Further information**

**Media:**

Katrine Sperling                     +45 3079 6718                     krsp@novonordisk.com
Ken Inchausti (US)                   +1 609 786 8316                   kiau@novonordisk.com

**Investors:**

Peter Hugreffe Ankersen              +45 3075 9085                     phak@novonordisk.com
Melanie Raouzeos                     +45 3075 3479                     mrz@novonordisk.com
Hanna Ögren                          +45 3079 8519                     haoe@novonordisk.com
Kasper Veje (US)                     +1 609 235 8567                   kpvj@novonordisk.com